← Back to Search

Antifibrinolytic Agent

Tranexamic Acid for Postoperative Complications

Phase < 1
Waitlist Available
Led By Riley McLean, MD
Research Sponsored by Riley McLean
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 minutes post initial injection
Awards & highlights

Study Summary

This trial will evaluate whether injecting tranexamic acid (TXA) before Mohs surgery can help reduce bleeding and pain during surgery, and lead to fewer post-operative complications.

Eligible Conditions
  • Skin Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from day of surgery to 12 weeks post-operation
This trial's timeline: 3 weeks for screening, Varies for treatment, and from day of surgery to 12 weeks post-operation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Postoperative Complications
Secondary outcome measures
Hemostasis
Injection Pain

Side effects data

From 2021 Phase 3 trial • 1226 Patients • NCT04733157
5%
Vomiting
2%
Dizziness
1%
Nausea
100%
80%
60%
40%
20%
0%
Study treatment Arm
Study Group/Group A_(Tranexamic Acid)
Control Group/Group B_(Placebo)

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Tranexamic acidExperimental Treatment2 Interventions
The TXA group will receive 2% lidocaine with 1:100,000 epinephrine mixed 50/50 with 50mg/ml TXA (with 50% dilution, this will yield 1% lidocaine with 1:200,000 epi).
Group II: ControlActive Control1 Intervention
The control group will use the routine local anesthetic of buffered 1% lidocaine with 1:200,000 epinephrine.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tranexamic acid injection
2021
Completed Phase 4
~3060
Lidocaine Epinephrine
2019
N/A
~170

Find a Location

Who is running the clinical trial?

Riley McLeanLead Sponsor
Riley McLean, MDPrincipal InvestigatorUniversity of Massachusetts, Worcester

Media Library

Tranexamic acid injection (Antifibrinolytic Agent) Clinical Trial Eligibility Overview. Trial Name: NCT04630886 — Phase < 1
Skin Cancer Research Study Groups: Tranexamic acid, Control
Skin Cancer Clinical Trial 2023: Tranexamic acid injection Highlights & Side Effects. Trial Name: NCT04630886 — Phase < 1
Tranexamic acid injection (Antifibrinolytic Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04630886 — Phase < 1
~51 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top